COMBINED THERAPY WITH ARBEKACIN AND FOSFOMYCIN FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS

We examined the clinical efficacy of a combination of arbekacin and fosfomycin in the treatment of various methicillin-resistant Staphylococcus aureus (MRSA) infections. The combination ofarbekacin plus fosfomycin displayed 65.4% (17/26) clinical efficacy and 65.4% (17/26) bacteriological efficacy....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Japanese journal of antibiotics 1994/06/25, Vol.47(6), pp.798-803
Hauptverfasser:	KONO, KENJI, TAKEDA, SEIJI, TATARA, ICHIRO, ARAKAWA, KIKUO, TANAKA, HIROAKI, MIYAKE, SHUNJI, MINAMIKAWA, HIROMICHI, HOSHINO, HIROSUKE, SATO, MIKIO, HATTORI, FUMITADA, KAWAHIRA, KOZABURO
Format:	Artikel
Sprache:	eng
Schlagworte:	Aminoglycosides Anti-Bacterial Agents Dibekacin - analogs & derivatives Dibekacin - therapeutic use Drug Therapy, Combination - therapeutic use Fosfomycin - pharmacology Fosfomycin - therapeutic use Humans Methicillin Resistance Microbial Sensitivity Tests Pseudomonas aeruginosa - drug effects Pseudomonas Infections - complications Pseudomonas Infections - drug therapy Staphylococcal Infections - complications Staphylococcal Infections - drug therapy Staphylococcus aureus - drug effects Superinfection - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We examined the clinical efficacy of a combination of arbekacin and fosfomycin in the treatment of various methicillin-resistant Staphylococcus aureus (MRSA) infections. The combination ofarbekacin plus fosfomycin displayed 65.4% (17/26) clinical efficacy and 65.4% (17/26) bacteriological efficacy. This combination thus appeared to be an effective regimen for the treatment of MRSA infections. However, its bacteriological efficacy against concomitant Pseudomonas aeruginosa strains was only 16.7% (1/6). In addition, in 4 episodes of superinfection involving P. aeruginosa strains developed during the combination therapy.
ISSN:	0368-2781 2186-5477
DOI:	10.11553/antibiotics1968b.47.798